ABAmer Beitinjaneh

Amer Beitinjaneh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amer Beitinjaneh has a total of 326 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Associations of Baseline Cognitive and Psychosocial Function with Clinical Outcomes After Autologous Stem Cell Transplantation in a Multiple Myeloma Sample

    by Maria Rueda-Lara, Krishna V. Komanduri, Denise Pereira, Lazaros Lekakis, Trent Peng Wang, Antonio M. Jimenez, Amer Beitinjaneh, Noa G. Holtzman, Damian J. Green, Mark Goodman, et al.

    Background/Objectives: Autologous stem cell transplantation (ASCT) remains a standard frontline treatment for eligible patients with multiple myeloma and is associated with improved progression-free survival and sustained treatment responses. In addition to medical eligibility factors, pre-treatment psychosocial variables such as depression and anxiety as well as cognitive functioning may influence short- and long-term transplant outcomes. This study examined the relationship between pre-transplant psychosocial and cognitive functioning and clinical outcomes in patients with multiple myeloma undergoing ASCT. Methods: Participants (n = 245) undergoing a standardized protocol for ASCT in Miami, Florida received pre-transplant psychosocial and neuropsychological assessments. Patient-reported clinical variables and cognitive performance were related to transplant success and transplant recovery outcomes, including time to engraftment, length of hospital stay post-engraftment, and survival across four timepoints. Results: While most patients achieved engraftment within a similar timeframe, the duration of hospitalization following engraftment varied considerably. Only higher baseline trait anxiety was associated with longer post-engraftment hospital stays. In multivariate Cox regression analyses, post-engraftment length of stay was independently associated with long-term mortality when modeled as a continuous variable. In a secondary analysis using an empirically derived cutoff corresponding to stays longer than the 80th percentile (≥7 days post-engraftment), both prolonged post-engraftment hospitalization and poorer baseline delayed memory was independently associated with mortality. Descriptive survival analyses further showed that patients with prolonged post-engraftment hospitalizations had higher overall mortality and shorter survival than those with shorter post-engraftment hospital stays. Conclusions: Patients who demonstrated poorer delayed memory performance pre-transplant and prolonged hospital admission post-transplant may be most vulnerable to dying when examined at long-term follow-up. Pre-transplant psychiatric assessments provide an opportunity to identify and potentially implement supportive care interventions for patients at increased risk for cognitive impairment.

  • Open Access

    Associations of Baseline Cognitive and Psychosocial Function With Clinical Outcomes After Autologous Stem Cell Transplantation in a Multiple Myeloma Sample

    by Maria Rueda-Lara, Krishna V. Komanduri, Denise Pereira, Lazaros Lekakis, Trent Peng Wang, Antonio M. Jimenez, Amer Beitinjaneh, Noa G. Holtzman, Damian J. Green, Mark Goodman, et al.

    Background/Objectives: Autologous stem cell transplantation (ASCT) remains a standard frontline treatment for eligible patients with multiple myeloma and is associated with im-proved progression-free survival and sustained treatment responses. In addition to medi-cal eligibility factors, pre-treatment psychosocial variables such as depression and anxiety as well as cognitive functioning may influence short and long-term transplant outcomes. This study examined the relationship between pre-transplant psychosocial and cognitive functioning and clinical outcomes in patients with multiple myeloma undergoing ASCT. Methods: Participants (N = 245) undergoing ASCT in Miami, Florida completed routine pre-transplant psychosocial and neuropsychological assessments. Patient-reported clini-cal variables and cognitive performance were examined in relation to transplant success and transplant recovery outcomes, including time to engraftment, length of hospital stay post-engraftment, and survival across four timepoints. Results: While most patients achieved engraftment within a similar timeframe, the duration of hospitalization follow-ing engraftment varied considerably. Higher baseline trait anxiety was associated with longer post-engraftment hospital stays. In multivariable Cox regression analyses, post-engraftment length of stay was independently associated with long-term mortality when modeled as a continuous variable. In a secondary analysis using an empirically de-rived cutoff corresponding to stays longer than the 80th percentile (≥7 days post-engraftment), both prolonged post-engraftment hospitalization and poorer baseline delayed memory were independently associated with mortality. Descriptive survival analyses further showed that patients with prolonged post-engraftment hospitalizations had higher overall mortality and shorter survival than those with shorter post-engraftment hospital stays. Conclusions: Patients who demonstrated delayed memory performance pre-transplant and prolonged hospital admission post-transplant may be most vulnerable to dying when examined at long-term follow-up. Pre-transplant psychiatric assessments provide an opportunity to identify potentially implement supportive care interventions for patients at increased vulnerability for cognitive impairment.

  • Open Access

    Dasatinib Exposure and Risk of CMV Reactivation in Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia

    by Lubna Osman‐Kardash, Ahmed Alnajar, Anthony D. Anderson, Ellen Madarang, Mikkael Sekeres, Justin Watts, Terrence Bradley, Wenhui Li, Jill Lykon, Mohammed Raja, et al.

  • Open Access

    Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival

    by Gurbakhash Kaur, Jennifer Logue, Ruta Brazauskas, Temitope Oloyede, Muhammad Bilal Abid, Sairah Ahmed, Mahmoud Aljurf, Rahul Banerjee, Asad Bashey, Amer M. Beitinjaneh, et al.


  • Open Access

    Clinical Characteristics and Outcomes of Invasive Aspergillosis in Patients with Hematological Malignancies and Transplantation and Cellular Therapies in the Contemporary Era

    by Christopher M. Lopez, Jose F. Suarez, Maria A. Mendoza, Anthony D. Anderson, Jill Lykon, Wenhui Li, Michele I. Morris, Yoichiro Natori, Mohammed Raja, Lazaros J. Lekakis, et al.

    Background: Despite important advancements in diagnostic modalities, routine use of therapeutic drug monitoring (TDM) and newer antifungal therapies, there is a paucity of contemporary data regarding clinical characteristics and outcomes of invasive aspergillosis (IA) in the United States. Methods: Single-center, retrospective cohort study of hospitalized patients between 2015 and 2020, who had active hematological malignancy (HM) or had undergone transplantation and cellular therapy (TCT) and had probable or proven IA. Results: Sixty-two patients with probable or proven IA, including 21 HM and 41 TCT, were identified. Forty-four percent of the cases corresponded to breakthrough IA. Bronchoalveolar lavage galactomannan was ≥ 1 in 71% and ≥ 0.5 in 88%, while serum galactomannan was ≥ 0.5 in only 34%. Among assessable patients (n = 59), 90-day partial or complete response to antifungal therapy occurred in 39%. All-cause mortality for the entire cohort was 22% at 30 days and 46% at 90 days. IA attributable mortality was 18% at 30 days and 38% at 90 days. Achieving therapeutic antifungal serum levels was associated with a reduction in all-cause mortality, while prior clinically significant CMV infection (aOR 9.65, 95% CI 1.34–69.6; P = 0.025) and relapsed/refractory hematological disease (aOR 8.5, 95% CI 2.23, 32.4; P = 0.002) were associated with higher IA attributable mortality. Conclusions: Despite advancements in diagnosis and treatment, IA remains associated with poor outcomes in hematological patients in the contemporary era. Newer antifungals and improved strategies for monitoring and prevention of IA in these vulnerable patient populations are urgently needed.


  • Acute Toxicities of Bone Marrow Donation in Unrelated Donors with Sickle Cell Trait: A Center for International Blood and Marrow Transplantation Research Analysis

    by Nosha Farhadfar, Stephanie Bo-Subait, Gabrielle Schmidt, Brent Logan, Mahmoud Aljurf, Sherif Badawy, Amer Beitinjaneh, Lohith Gowda, Kimberly A. Kasow, Matthew Seftel, et al.


  • Top Cited Papers

    Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma

    by Roni Shouval, Christopher Strouse, Soyoung Kim, Temitope Oloyede, Sairah Ahmed, Farrukh T. Awan, Danny Luan, Veronika Bachanova, Talha Badar, Merav Bar, et al.


  • Open Access

    Impact of Race and Ethnicity on Outcomes After Umbilical Cord Blood Transplantation

    by Karen Ballen, Tao Wang, Naya He, Jennifer M. Knight, Sanghee Hong, Haydar Frangoul, Leo F. Verdonck, Amir Steinberg, Miguel A. Diaz, C. Fred LeMaistre, et al.


  • Open Access

    A US Multicenter Collaborative Study on Outcomes of Hematopoietic Cell Transplantation in Hepatosplenic T-Cell Lymphoma

    by Muhamad Alhaj Moustafa, Jeremy L. Ramdial, Athanasios Tsalatsanis, Farhad Khimani, Bhagirathbhai Dholaria, Leyla Bojanini, Taylor Rey Brooks, Jasmine Zain, N. Nora Bennani, Zachary Braunstein, et al.


  • Top Cited Papers
    Open Access

    Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study

    by Michael Wang, Javier Munoz, Andre Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Houston Holmes, Samantha Jaglowski, Ian W. Flinn, et al.

    PURPOSE: Brexucabtagene autoleucel (KTE-X19) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL). Outcomes after a 3-year follow-up in the pivotal ZUMA-2 study of KTE-X19 in relapsed/refractory MCL are reported, including for subgroups by prior therapy (bendamustine and type of Bruton tyrosine kinase inhibitor [BTKi]) or high-risk characteristics. METHODS: Patients with relapsed/refractory MCL (one to five prior therapies, including prior BTKi exposure) received a single infusion of KTE-X19 (2 × 106 CAR T cells/kg). RESULTS: After a median follow-up of 35.6 months, the objective response rate among all 68 treated patients was 91% (95% CI, 81.8 to 96.7) with 68% complete responses (95% CI, 55.2 to 78.5); medians for duration of response, progression-free survival, and overall survival were 28.2 months (95% CI, 13.5 to 47.1), 25.8 months (95% CI, 9.6 to 47.6), and 46.6 months (95% CI, 24.9 to not estimable), respectively. Post hoc analyses showed that objective response rates and ongoing response rates were consistent among prespecified subgroups by prior BTKi exposure or high-risk characteristics. In an exploratory analysis, patients with prior bendamustine benefited from KTE-X19, but showed a trend toward attenuated T-cell functionality, with more impact of bendamustine given within 6 versus 12 months of leukapheresis. Late-onset toxicities were infrequent; only 3% of treatment-emergent adverse events of interest in ZUMA-2 occurred during this longer follow-up period. Translational assessments revealed associations with long-term benefits of KTE-X19 including high-peak CAR T-cell expansion in responders and the predictive value of minimal residual disease for relapse. CONCLUSION: These data, representing the longest follow-up of CAR T-cell therapy in patients with MCL to date, suggest that KTE-X19 induced durable long-term responses with manageable safety in patients with relapsed/refractory MCL and may also benefit those with high-risk characteristics.